4 hours Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to Neutral at Cantor Fitzgerald MarketBeat
Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday.
Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday.